233 related articles for article (PubMed ID: 19286997)
1. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.
Throm RE; Ouma AA; Zhou S; Chandrasekaran A; Lockey T; Greene M; De Ravin SS; Moayeri M; Malech HL; Sorrentino BP; Gray JT
Blood; 2009 May; 113(21):5104-10. PubMed ID: 19286997
[TBL] [Abstract][Full Text] [Related]
2. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.
van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Hacein-Bey-Abina S; Nordling DL; Cavazzana-Calvo M; Thrasher AJ; Williams DA; Reeves L; Malik P
Gene Ther; 2012 Aug; 19(8):872-6. PubMed ID: 22551777
[TBL] [Abstract][Full Text] [Related]
3. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
[TBL] [Abstract][Full Text] [Related]
4. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
[TBL] [Abstract][Full Text] [Related]
5. Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.
Feldman SA; Xu H; Black MA; Park TS; Robbins PF; Kochenderfer JN; Morgan RA; Rosenberg SA
Hum Gene Ther Methods; 2014 Aug; 25(4):253-60. PubMed ID: 25072603
[TBL] [Abstract][Full Text] [Related]
6. Self-inactivating lentiviral vectors with U3 and U5 modifications.
Iwakuma T; Cui Y; Chang LJ
Virology; 1999 Aug; 261(1):120-32. PubMed ID: 10441560
[TBL] [Abstract][Full Text] [Related]
7. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration.
Loew R; Meyer Y; Kuehlcke K; Gama-Norton L; Wirth D; Hauser H; Stein S; Grez M; Thornhill S; Thrasher A; Baum C; Schambach A
Gene Ther; 2010 Feb; 17(2):272-80. PubMed ID: 19865181
[TBL] [Abstract][Full Text] [Related]
8. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.
Schambach A; Mueller D; Galla M; Verstegen MM; Wagemaker G; Loew R; Baum C; Bohne J
Gene Ther; 2006 Nov; 13(21):1524-33. PubMed ID: 16763662
[TBL] [Abstract][Full Text] [Related]
9. Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line.
Greene MR; Lockey T; Mehta PK; Kim YS; Eldridge PW; Gray JT; Sorrentino BP
Hum Gene Ther Methods; 2012 Oct; 23(5):297-308. PubMed ID: 23075105
[TBL] [Abstract][Full Text] [Related]
10. Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination.
Lee CL; Chou M; Dai B; Xiao L; Wang P
Biotechnol Bioeng; 2012 Jun; 109(6):1551-60. PubMed ID: 22179950
[TBL] [Abstract][Full Text] [Related]
11. 3' self-inactivating long terminal repeat inserts for the modulation of transgene expression from lentiviral vectors.
Manic G; Maurin-Marlin A; Galluzzi L; Subra F; Mouscadet JF; Bury-Moné S
Hum Gene Ther Methods; 2012 Apr; 23(2):84-97. PubMed ID: 22456436
[TBL] [Abstract][Full Text] [Related]
12. Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection.
van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Baum C; Thrasher AJ; Williams DA; Nordling DL; Reeves L; Malik P
Gene Ther; 2012 Mar; 19(3):246-54. PubMed ID: 21753795
[TBL] [Abstract][Full Text] [Related]
13. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
[TBL] [Abstract][Full Text] [Related]
14. Generation of High-Titer Self-Inactivated γ-Retroviral Vector Producer Cells.
Ghani K; Boivin-Welch M; Roy S; Dakiw-Piaceski A; Barbier M; Pope E; Germain L; Caruso M
Mol Ther Methods Clin Dev; 2019 Sep; 14():90-99. PubMed ID: 31312667
[TBL] [Abstract][Full Text] [Related]
15. Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization.
Hu P; Bi Y; Ma H; Suwanmanee T; Zeithaml B; Fry NJ; Kohn DB; Kafri T
Gene Ther; 2018 Oct; 25(7):454-472. PubMed ID: 30190607
[TBL] [Abstract][Full Text] [Related]
16. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration.
Logan AC; Haas DL; Kafri T; Kohn DB
J Virol; 2004 Aug; 78(16):8421-36. PubMed ID: 15280451
[TBL] [Abstract][Full Text] [Related]
17. Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells.
Bosticardo M; Ghosh A; Du Y; Jenkins NA; Copeland NG; Candotti F
Mol Ther; 2009 Nov; 17(11):1910-8. PubMed ID: 19638958
[TBL] [Abstract][Full Text] [Related]
18. gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function.
Hacein-Bey H; Cavazzana-Calvo M; Le Deist F; Dautry-Varsat A; Hivroz C; Rivière I; Danos O; Heard JM; Sugamura K; Fischer A; De Saint Basile G
Blood; 1996 Apr; 87(8):3108-16. PubMed ID: 8605324
[TBL] [Abstract][Full Text] [Related]
19. Self-inactivating alpharetroviral vectors with a split-packaging design.
Suerth JD; Maetzig T; Galla M; Baum C; Schambach A
J Virol; 2010 Jul; 84(13):6626-35. PubMed ID: 20410274
[TBL] [Abstract][Full Text] [Related]
20. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors.
Xu K; Ma H; McCown TJ; Verma IM; Kafri T
Mol Ther; 2001 Jan; 3(1):97-104. PubMed ID: 11162316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
